A systematic evaluation of the attributable mortality of Stenotrophomonas maltophilia bacteremia was undertaken in a matched, retrospective, case-control study. We determined the attributable mortality rate (26.7%) and mortality risk ratio (an 8-fold increase) of S. maltophilia bacteremia. The attributable mortality rate for S. maltophilia bacteremia is similar to the attributable mortality rate for other nosocomial bloodstream infections.
with S. maltophilia bacteremia have had a range of 21%-69% [9, 10] . However, many patients with S. maltophilia bacteremia have significant underlying illnesses. In addition, the organism is often recovered from mixed cultures. Therefore, the proportion of deaths directly attributable to S. maltophilia bacteremia remains unclear.
Attributable mortality is a measure of the effect of a given disease on mortality rates and provides an estimate of the contribution of one particular factor to overall mortality [11] . To improve the understanding of attributable mortality associated with S. maltophilia bacteremia, we conducted a matched, retrospective, case-control study that used stringent criteria to exclude polymicrobial bacteremia. We also assessed risk factors associated with a fatal outcome and the effect of antimicrobial therapy on survival.
Patients and methods. A case patient was defined as any patient aged у18 years for whom у1 blood culture yielded S. maltophilia in the 6.5-year period of January 1991-August 1997. A control patient was defined as a patient similar to a case patient who had been hospitalized during the same period studied but who did not have S. maltophilia bacteremia.
We identified patients by reviewing the clinical microbiology laboratory's daily report list. To avoid any confounding, potential case patients were excluded if any other species of bacteria was isolated from the same set of blood cultures or from blood cultures performed in the 72 h before isolation of S. maltophilia. Once a patient was identified as a case patient or a control patient, a trained research nurse collected relevant clinical information by reviewing the patient's charts. An infectious diseases fellow reviewed the discharge summaries and did a supplemental review of medical records, when necessary. Information was obtained regarding demographic characteristics and relevant laboratory and clinical data, including underlying diseases, major surgical and other invasive procedures, length of intensive care unit and hospital stay, antibiotic exposure (by agent and day of exposure), and mortality. This information was entered into a database for statistical analysis.
Blood samples were inoculated onto aerobic and anaerobic media and processed by the ESP 384 blood culture system (Accumed International). Identification and antimicrobial susceptibility testing of isolated bacteria were performed in the Clinical Microbiology Laboratory at New England Medical Center (Boston) using the Vitek automated system for identification (bioMérieux Vitek) and Kirby-Bauer disk testing for susceptibility [12] .
Each case patient was matched to the most suitable control patient on a subject-by-subject basis in a stepwise procedure [13, 14] . First, we used our hospital's computerized medical record system to obtain a list of potential control patients that was based on the following matching criteria: same underlying disease, similar age ‫01ע(‬ years), same sex, and same duration of hospitalization before the onset of bacteremia. The codes of the International Classification of Diseases, 9th revision, were used to screen for potential matches with regard to primary underlying disease; discharge summaries of patients were also reviewed to confirm the diagnosis. Underlying disease was given first priority; then, control patients were selected in a hierarchical fashion. Next, we grouped several potential control patients with the corresponding case patient, and, for each case patient, we selected the best control patient who met у1 of the following additional criteria: same age ‫5ע(‬ years) and same sex. The duration of hospitalization before detection of S. maltophilia was also a matching criterion. The control duration of hospitalization was selected as the time of admission to the time of the last negative blood culture. Case patients and control patients were observed until discharge from the hospital or death. Appropriate therapy was defined as a regimen that included у1 antimicrobial agent to which the organism was susceptible in vitro.
The attributable mortality was defined as the excess mortality associated with S. maltophilia bacteremia. The rate was calculated as the difference between the crude mortality rate for case patients and matched control patients. We estimated the mortality risk ratio (the relative risk of death of bacteremic patients compared with control patients) by dividing the crude mortality rate for case patients by the crude mortality rate for control patients (done using SAS software; SAS Institute). We determined the 95% CIs of the attributable mortality rates by tests for the difference of proportions. We used the CochranMantel-Haenszel test for comparison of mortality rates between case patients and control patients to determine statistical significance [15] . We identified risk factors for fatal outcome with use of the Cox proportional hazard regression test [16] . Proportions were compared by means of the x 2 or Fisher's exact test, as appropriate. Continuous variables were compared by use of Student's t test or the Mann-Whitney U test, as indicated. For comparison of excess length of stay, the Wilcoxon signedrank test was performed. All P values were 2 tailed; P р .05 was considered statistically significant.
Results. We identified 37 cases of S. maltophilia bacteremia during this study. We excluded 7 cases from the study (1 because the medical record could not be found and 6 because the bacteremia was polymicrobial), which left a total of 30 cases. We matched the 30 case patients with 30 control patients. Table 1 lists the characteristics of the case and control patients. All case patients and control patients were correctly matched for underlying disease, age, and sex. Of the 60 patients (30 pairs), 40 (66.7%) had an underlying hematologic or neoplastic disorder, 20 (50%) of whom had acute myelocytic leukemia. The median duration of hospital stay before the onset of bacteremia in the S. maltophilia group was similar to the duration of hospitalization for control patients.
Comparison of case patients with control patients for predisposing risk factors for S. maltophilia bacteremia revealed that case patients were more likely to have a CVC in place (P p ) and to have received previous aminoglycoside therapy .05 ( ). Presence of neutropenia, prolonged neutropenia, P p .01 and other risk factors were not more likely to be present in case patients.
The identified sources of bacteremia among case patients were associated with a CVC (43.3%), were pulmonary (13.3%), were at soft-tissue sites (6%), and were intra-abdominal (6%). Nine case patients (30%) had no apparent primary source of infection, but all had CVCs in place.
The mortality rate for the case patients was 30%, compared with a mortality rate of 3.3% for control patients. The attributable mortality was 26.7% (95% CI, 9-44), with a risk ratio of 8 for death (95% CI, 1.3-48.5;
). The median duration of P p .0006 hospitalization was slightly longer for the case patients than it was for controls (11.5 vs. 8 days), but this difference was not statistically significant ( ). P p .62 At the time of the initial case of bacteremia, 66.7% of case patients had a temperature of у38ЊC, 43.3% had rigors, and 23.3% had leukocytosis (WBC count, 1 cells/L). An 9 10 ϫ 10 acute decrease in systolic blood pressure to !90 mm Hg was seen in 43.3% of case patients. Severity of illness at the time of initial bacteremia, as indicated by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, was significantly greater among case patients (mean score, 16.4 vs. 9.9;
). P p .005
All isolates were resistant in vitro to imipenem. Of the agents tested, trimethoprim-sulfamethoxazole and ciprofloxacin had the best in vitro activity; 89.6% and 86.2% of the isolates were susceptible to these agents, respectively. Most isolates were resistant in vitro to aminoglycoside and b-lactam antibiotics.
Once bacteremia was diagnosed, all case patients were treated with antibiotics. The mortality rate was lower among patients who received appropriate therapy (3 [14.3%] of 21 patients) than it was among patients who did not (6 [75%] of 8; P p ). One patient could not be evaluated because the results .0002 of susceptibility tests were not available. Most of the case patients (18 [86%] of 21) received appropriate therapy р48 h after the onset of bacteremia; 3 died despite having received early appropriate therapy. Because the number of patients receiving monotherapy with a sensitive agent was too small (2 patients), examination of outcomes comparing monotherapy to combination therapy could not be performed. Univariate analysis of the risk factors for mortality showed that appropriate therapy was significantly protective (relative risk, 0.2; 95% CI, 0.07-0.67; ), whereas the presence of P ! .01 neutropenia (relative risk, 5.5; 95% CI, 1.8-16.9; ) in-P ! .01 creased the risk.
Discussion. Despite the recognition of S. maltophilia as a significant pathogen, to our knowledge, no study has systematically evaluated the attributable mortality of S. maltophilia bacteremia [9] . We found an excess mortality of 26.7% (95% CI, 9-44) attributable to S. maltophilia bacteremia. Although some previous studies have reported attributable mortality rates ranging from 12.5% to 41%, the criteria for attributing death to bacteremia were not specified [9, 10, 15] . The use of a welldesigned, matched, historical cohort study is particularly helpful in these circumstances [11, 16] . In our study design, adequate matching between case patients and control patients eliminated the influence of comorbid conditions to control for the confounding effects of underlying disease. All case and control patients were similar with regard to the distribution of underlying disease, age, sex, and duration of exposure. Another concern raised by previous analysis of S. maltophilia bacteremia regarding the significance of S. maltophilia as a direct cause of mortality was its frequent recovery from mixed cultures [17] . We specifically excluded all cases of polymicrobial bacteremia. Our analysis of risk factors for mortality showed that inappropriate antimicrobial therapy and neutropenia were risk factors for death. Because of the relatively small number of deaths, the independence of these associations could not be assessed.
Other studies have examined attributable mortality for other organism-specific bloodstream infections; the attributable mortality for candidemia has been estimated to be 38%; the attributable mortality for enterococcal bacteremia, 31%; the attributable mortality for Bacteroides fragilis-group bacteremia, 19%; and that associated with coagulase-negative staphylococcal bacteremia, 13.6% [12, 13, 16, 18] . These matched casecontrol studies used a similar study design. Thus, the mortality attributable to S. maltophilia bacteremia is higher than that for B. fragilis-group and coagulase-negative staphylococcal bacteremia, and it is lower than that for candidemia and enterococcal bacteremia. Our results indicate a mortality rate comparable with the 26%-28% attributable mortality rates reported for most nosocomial bloodstream infections from a small number of controlled studies [19, 20] .
In studies published elsewhere, the factors found to be most commonly associated with S. maltophilia bacteremia were presence of malignancy, increased duration of hospitalization before bacteremia, previous receipt of broad-spectrum antibiotic therapy, presence of a CVC, and prolonged neutropenia [8, 21] . We could not analyze underlying illness and prolonged hospitalization as predisposing factors because these were matching variables in our study. However, it is noteworthy that 68% of the patients in the present study had an underlying malignancy, and one-half of those patients had acute leukemia. Duration of hospitalization before bacteremia was found to be 111.5 days for patients with S. maltophilia. Among factors that potentially predispose to infection, the presence of a CVC and previous therapy with an aminoglycoside were significantly associated with S. maltophilia.
Treatment of S. maltophilia infection is difficult because of the almost universal resistance to commonly used broad-spectrum antibiotics. Our data suggest that appropriate treatment improves the likelihood of survival, as is often the case with multidrugresistant organisms [4, 9, 10, 21] . Limited clinical data suggest that combination treatment of severe infections with S. maltophilia is preferred and is associated with a lower mortality rate [9] . Because of the small numbers of cases, our data were insufficient to confirm that combination therapy with 2 active agents lowered mortality rates. In summary, our data demonstrate significant mortality attributable to S. maltophilia. Patients who received appropriate therapy experienced reduced likelihood of death.
